impact on continuous acceleromyography use for intraoperative period

impact on continuous acceleromyography use for intraoperative period - impact on continuous acceleromyography use for intraoperative period

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000040272

Enrollment

Registered

2020-04-30

Start date

2020-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

elective surgery patient

Interventions

Using acceleromyography during surgery Using rocuronium effect site concentration concentration during surgery

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients undergoing elective surgery under general anesthesia

Exclusion criteria

Exclusion criteria: Neuromuscular diseases, Taking drugs that interact with muscle relaxants, BMI of 30 or more, Chronic renal failure, Cirrhosis.

Design outcomes

Primary

Measure	Time frame
Intraoperative complications such as backing	—

Secondary

Measure	Time frame
Rocuronium dose, TOF value at the end of surgery, amount of sugammadex required to antagonize rocuronium	—

Countries

Japan

Contacts

Public ContactTakayuki Hasegawa

Iwaki City Medical Center anesthesiology

tahasegawa-fks@nmin.ac.jp0246-26-3151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026